(Circulation. 2000;102:2228.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Peripheral Arterial Disease in Randomized Trial of Estrogen With Progestin in Women With Coronary Heart Disease
The Heart and Estrogen/Progestin Replacement Study
From the Department of Medicine (J.H.), George Washington University, Washington, DC; the Departments of General Internal Medicine, San Francisco VA Medical Center (J.A.S.) and Epidemiology and Biostatistics (J.A.S., F.L.), University of California, San Francisco; the Department of Medicine (W.B.A.), Wake Forest University, Winston-Salem, NC; the Department of Orthopaedic Surgery (M.T.V.), University of Pittsburgh, Pittsburgh, Pa; the Heart Disease Prevention Clinic (D.H.), University of Minnesota, Minneapolis; and Wyeth-Ayerst Research (M.C.), Radnor, Pa.
Correspondence to Dr Judith Hsia, 2150 Pennsylvania Ave NW #4-414, Washington, DC 20037. E-mail domjah{at}gwumc.edu
Background—Postmenopausal estrogen use has been associated with reduced carotid atherosclerosis in observational studies, but this relationship has not been confirmed in a clinical trial. The impact of estrogen on atherosclerotic disease in other peripheral arteries is unknown.
Methods and Results—Postmenopausal women with coronary heart disease (CHD) and an intact uterus (n=2763) were randomly assigned to conjugated equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) daily or to placebo in a secondary CHD prevention trial. This analysis focuses on incident peripheral arterial procedures and deaths in the 2 treatment groups; peripheral vascular disease was a predefined secondary outcome. During a mean of 4.1 years of follow-up, 311 peripheral arterial events were reported in 213 women, an annual incidence of 2.9%. The number of women who had peripheral arterial events was 99 among those assigned to active estrogen/progestin and 114 among those assigned to placebo, a nonsignificant difference (relative hazard 0.87, 95% CI 0.66 to 1.14). In the placebo group, hypertension and diabetes mellitus were independently associated with higher rates of peripheral arterial events, and plasma HDL cholesterol and body mass index were associated with lower rates of peripheral arterial events. In the estrogen/progestin group, current smoking and diabetes were independent predictors of peripheral arterial events. Incident peripheral arterial disease was not a significant predictor of coronary, cardiovascular, or total mortality.
Conclusions—Treatment with oral conjugated estrogen plus medroxyprogesterone acetate was not associated with a significant reduction in incident peripheral arterial events in postmenopausal women with preexisting CHD.
Key Words: hormones • peripheral vascular disease • coronary disease • women
This article has been cited by other articles:
 |
|
 |
|
  V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Pradhan, S. Shrivastava, N. R. Cook, N. Rifai, M. A. Creager, and P. M Ridker Symptomatic Peripheral Arterial Disease in Women: Nontraditional Biomarkers of Elevated Risk Circulation, February 12, 2008; 117(6): 823 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Voci, F. Pizzuto, and F. Romeo Coronary flow: a new asset for the echo lab? Eur. Heart J., November 1, 2004; 25(21): 1867 - 1879. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hultgren, P. Olofsson, and E. Wahlberg Reproductive History in Women with Lower Limb Ischemia Angiology, July 1, 2004; 55(4): 373 - 383. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. O'Hare, E. Vittinghoff, J. Hsia, and M. G. Shlipak Renal Insufficiency and the Risk of Lower Extremity Peripheral Arterial Disease: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) J. Am. Soc. Nephrol., April 1, 2004; 15(4): 1046 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hsia, M. H. Criqui, R. J. Rodabough, R. D. Langer, H. E. Resnick, L. S. Phillips, M. Allison, D. E. Bonds, K. Masaki, P. Caralis, et al. Estrogen Plus Progestin and the Risk of Peripheral Arterial Disease: The Women's Health Initiative Circulation, February 10, 2004; 109(5): 620 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Korovkina, A. M. Brainard, P. Ismail, T. J. Schmidt, and S. K. England Estradiol Binding to Maxi-K Channels Induces Their Down-regulation via Proteasomal Degradation J. Biol. Chem., January 9, 2004; 279(2): 1217 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor An Epidemiologist Looks at Hormones and Heart Disease in Women J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4031 - 4042. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, M. Hlatky, J. Hsia, S. Hulley, A. Herd, S. Khan, et al. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) JAMA, July 3, 2002; 288(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Hlatky, D. Boothroyd, E. Vittinghoff, P. Sharp, M. A. Whooley, and for the HERS Research Group Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy: Results From the Heart and Estrogen/Progestin Replacement Study (HERS) Trial JAMA, February 6, 2002; 287(5): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Voci and F. Pizzuto Coronary flow: how far can we go with echocardiography? J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1885 - 1887. [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]
|
|